Accueil / Communiqués / Zoetis Reports Fourth Quarter and Full Year 2018 Results

Zoetis Reports Fourth Quarter and Full Year 2018 Results

Thursday, February 14th 2019 at 12:00pm UTC
  • For Fourth Quarter 2018, Zoetis Reports Revenue of $1.6 Billion,
    Growing 7%, and Net Income of $345 Million, or $0.71 per Diluted
    Share, on a Reported Basis

    • Reports Adjusted Net Income of $382 Million, or Adjusted
      Diluted EPS of $0.79, for Fourth Quarter 2018
    • Delivers 11% Operational Growth in Revenue and 21% Operational
      Growth in Adjusted Net Income for Fourth Quarter 2018
  • For Full Year 2018, Zoetis Reports Revenue of $5.8 Billion, Growing
    10%, and Net Income of $1.4 Billion, or $2.93 per Diluted Share, on a
    Reported Basis

    • Reports Adjusted Net Income of $1.5 Billion, or Adjusted
      Diluted EPS of $3.13, for Full Year 2018
    • Delivers 10% Operational Growth in Revenue and 31% Operational
      Growth in Adjusted Net Income for Full Year 2018
  • Provides Full Year 2019 Revenue Guidance of $6.175 – $6.300
    Billion, with Diluted EPS of $2.83 – $2.99 on a Reported Basis, or
    $3.42 – $3.52 on an Adjusted Basis

PARSIPPANY, N.J.–(BUSINESS WIRE)– Zoetis
Inc
. (NYSE:ZTS) today reported its financial results for the fourth
quarter and full year 2018 and provided full year guidance for 2019.
Financial results for the quarter and year include the impact of the
acquisition of Abaxis.

The company reported revenue of $1.6 billion for the fourth quarter of
2018, which was an increase of 7% compared with the fourth quarter of
2017. Net income for the fourth quarter of 2018 was $345 million, or
$0.71 per diluted share, compared with $81 million, or $0.16 per diluted
share, in the fourth quarter of 2017.

Adjusted net income1 for the fourth quarter of 2018 was $382
million, or $0.79 per diluted share, an increase of 12% and 14%,
respectively. Adjusted net income for the fourth quarter of 2018
excludes the net impact of $37 million for purchase accounting
adjustments, acquisition-related costs and certain significant items.

On an operational2 basis, revenue for the fourth quarter of
2018, excluding the impact of foreign exchange, increased 11% compared
with the fourth quarter of 2017. Adjusted net income for the fourth
quarter of 2018 increased 21% operationally, excluding the impact of
foreign exchange.

For full year 2018, the company reported revenue of $5.8 billion, an
increase of 10% compared with full year 2017. Net income for full year
2018 was $1.4 billion, or $2.93 per diluted share, an increase of 65%
and 67%, respectively.

Adjusted net income for full year 2018 was $1.5 billion, or
$3.13 per diluted share, an increase of 29% and 30%, respectively.
Adjusted net income for full year 2018 excludes the net impact of $97
million for purchase accounting adjustments, acquisition-related costs
and certain significant items.

On an operational basis, revenue for full year 2018 increased 10%,
excluding the impact of foreign exchange. Adjusted net income for full
year 2018 increased 31% operationally, excluding the impact of foreign
exchange.

EXECUTIVE COMMENTARY

“Zoetis delivered another year of strong performance in 2018 and
executed on investment plans that continue to strengthen our product
portfolio across the continuum of care,” said Juan Ramón Alaix, Chief
Executive Officer of Zoetis. “We achieved operational revenue growth for
the year of 10%, growing revenue across all of our core species, major
markets and therapeutic areas. We also grew our adjusted net income
faster than sales, at 31% operationally, as we continue to deliver on
our long-term value proposition.”

“Looking ahead, we will continue to build on our strategic investment
plans to support the growth of our core business, and in evolving spaces
such as diagnostics, devices, digital and data analytics. For full year
2019, we expect operational growth of 7.5% to 9.5% in revenue and 8% to
11% in adjusted net income. We remain committed to funding investments
that will help us maintain our leadership and growth, while returning
excess capital to shareholders.”

QUARTERLY HIGHLIGHTS

Zoetis organizes and manages its commercial operations across two
regional segments: the United States (U.S.) and International. Within
these segments, the company delivers a diverse portfolio of products for
livestock and companion animals tailored to local trends and customer
needs. In the fourth quarter of 2018:

  • Revenue in the U.S. segment was $809 million, an increase of
    14% compared with the fourth quarter of 2017. Sales of companion
    animal products grew 26% driven primarily by the acquisition of
    Abaxis, our key dermatology portfolio, and new products, including
    Simparica®. Growth in our companion animal business was
    partially offset by lower sales of certain in-line products due to
    anticipated competition. Sales of livestock products grew 3% in the
    quarter with all species contributing to growth. Growth in our cattle
    business was primarily due to higher sales of premium products, as
    well as competitor supply constraints. Poultry business growth was
    largely due to increased sales of alternatives to antibiotic medicated
    feed additives, while our swine business growth was the result of
    promotional efforts that drove increased demand across our therapeutic
    portfolio.
  • Revenue in the International segment was $727 million, a
    decrease of 2% on a reported basis and an increase of 5% operationally
    compared with the fourth quarter of 2017. Sales of companion animal
    products grew 7% on a reported basis and 14% on an operational basis.
    Growth resulted primarily from the acquisition of Abaxis,
    parasiticides (Simparica for dogs and Stronghold® Plus for
    cats), and increased sales across our key dermatology portfolio. Sales
    of livestock products declined 6% on a reported basis and grew 2%
    operationally; poultry, swine and fish all exhibited growth, while
    cattle was relatively flat in the quarter. Increased revenue in
    poultry products was the result of solid performance in other emerging
    markets, including Egypt and Indonesia. Growth in our swine business
    was largely driven by the recently launched Suvaxyn® PCV
    combo and PRRS vaccines in Europe, as well as strong demand for our
    products in other emerging markets. Our fish business grew due to
    market share gains of our PD vaccines in both the UK and Norway, as
    well as the continued growth of our LiVac® SRS vaccine in
    Chile.

Zoetis continues to drive demand and strengthen its diverse portfolio
through product lifecycle innovations, as well as expansion of key
products into new geographies. Since our last quarterly earnings
announcement:

  • Zoetis received approval in the U.S. and Canada for Revolution®
    Plus
    (selamectin and sarolaner topical solution), a new
    combination topical product for cats and kittens that provides
    parasite protection against fleas, ticks, ear mites, roundworms,
    hookworms and heartworms. Revolution Plus combines the proven
    broad-spectrum protection of selamectin with the advanced flea- and
    tick-killing power of sarolaner. This first-of-its-kind product
    exemplifies Zoetis’ dedication to innovation in parasiticides and
    builds on the 20-year trusted legacy of feline Revolution.
  • The company also continued to bring its newest leading canine products
    to additional markets. Cytopoint®
    (lokivetmab), a monoclonal antibody that is part of Zoetis’ canine
    dermatology portfolio, and Simparica, an oral flea and tick
    medication for dogs, both received additional approvals in countries
    in Asia and the Middle East.

FINANCIAL GUIDANCE

Zoetis is providing full year 2019 guidance, which includes:

  • Revenue between $6.175 billion to $6.300 billion
  • Reported diluted EPS between $2.83 to $2.99
  • Adjusted diluted EPS between $3.42 to $3.52

This guidance reflects foreign exchange rates as of late January.
Additional details on guidance are included in the financial tables and
will be discussed on the company’s conference call this morning.

WEBCAST & CONFERENCE CALL DETAILS

Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today,
during which company executives will review fourth quarter and full year
2018 results, discuss financial guidance and respond to questions from
financial analysts. Investors and the public may access the live webcast
by visiting the Zoetis website at http://investor.zoetis.com/events-presentations.
A replay of the webcast will be archived and made available on Feb. 14,
2019.

About Zoetis

Zoetis
is the leading animal health company, dedicated to supporting its
customers and their businesses. Building on more than 65 years of
experience in animal health, Zoetis discovers, develops, manufactures
and commercializes medicines, vaccines and diagnostic products, which
are complemented by biodevices, genetic tests and a range of services.
Zoetis serves veterinarians, livestock producers and people who raise
and care for farm and companion animals with sales of its products in
more than 100 countries. In 2018, the company generated annual revenue
of $5.8 billion with approximately 10,000 employees. For more
information, visit www.zoetis.com.

1 Adjusted net income and its components and
adjusted diluted earnings per share (non-GAAP financial measures) are
defined as reported net income attributable to Zoetis and reported
diluted earnings per share, excluding purchase accounting adjustments,
acquisition-related costs and certain significant items.

2 Operational revenue growth (a non-GAAP financial
measure) is defined as growth excluding the impact of foreign exchange.

DISCLOSURE NOTICES

Forward-Looking Statements: This
press release contains forward-looking statements, which reflect the
current views of Zoetis with respect to business plans or prospects,
future operating or financial performance, future guidance, future
operating models, expectations regarding products, expectations
regarding the performance of acquired companies and our ability to
integrate new businesses, expectations regarding the financial impact of
acquisitions, future use of cash and dividend payments, tax rate and tax
regimes, changes in the tax regimes and laws in other jurisdictions, and
other future events. These statements are not guarantees of future
performance or actions. Forward-looking statements are subject to risks
and uncertainties. If one or more of these risks or uncertainties
materialize, or if management’s underlying assumptions prove to be
incorrect, actual results may differ materially from those contemplated
by a forward-looking statement. Forward-looking statements speak only as
of the date on which they are made. Zoetis expressly disclaims any
obligation to update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise. A further list
and description of risks, uncertainties and other matters can be
found
in our Annual Report on Form 10-K for the fiscal year ended December 31,
2018, including in the sections thereof captioned “Forward-Looking
Statements and Factors That May Affect Future Results” and “Item 1A.
Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current
Reports on Form 8-K. These filings and subsequent filings are available
online at 
www.sec.govwww.zoetis.com,
or on request from Zoetis.

Use of Non-GAAP Financial Measures:
We use non-GAAP financial measures, such as adjusted net income,
adjusted diluted earnings per share and operational results (which
exclude the impact of foreign exchange), to assess and analyze our
results and trends and to make financial and operational decisions. We
believe these non-GAAP financial measures are also useful to investors
because they provide greater transparency regarding our operating
performance. The non-GAAP financial measures included in this press
release should not be considered alternatives to measurements required
by GAAP, such as net income, operating income, and earnings per share,
and should not be considered measures of liquidity. These non-GAAP
financial measures are unlikely to be comparable with non-GAAP
information provided by other companies. Reconciliation of non-GAAP
financial measures and GAAP financial measures are included in the
tables accompanying this press release and are posted on our website at
www.zoetis.com.

Internet Posting of Information:
We routinely post information that may be important to investors in the
‘Investors’ section of our website at
www.zoetis.com,
on our Facebook page at
http://www.facebook.com/zoetis
and on
Twitter
@zoetis
. We encourage investors and potential investors to
consult our website regularly and to follow us on Facebook and Twitter
for important information about us.

                         

ZOETIS INC.

CONSOLIDATED STATEMENTS OF INCOME(a)

(UNAUDITED)

(millions of dollars, except per share data)

               
 
Fourth Quarter Full Year
2018     2017 % Change 2018     2017 % Change
Revenue $ 1,564 $ 1,460 7 $ 5,825 $ 5,307 10
Costs and expenses:
Cost of sales(b) 544 457 19 1,911 1,775 8
Selling, general and administrative expenses(b) 420 361 16 1,484 1,334 11
Research and development expenses(b) 125 110 14 432 382 13
Amortization of intangible assets(c) 39 23 70 117 91 29
Restructuring charges and certain acquisition-related costs 14 12 17 68 19 *
Interest expense 59 50 18 206 175 18
Other (income)/deductions–net (55 ) 17   * (83 ) 6   *
Income before provision for taxes on income 418 430 (3) 1,690 1,525 11
Provision for taxes on income 73   350   (79) 266   663   (60)
Net income before allocation to noncontrolling interests 345 80 * 1,424 862 65
Less: Net (loss)/income attributable to noncontrolling interests   (1 ) (100) (4 ) (2 ) 100
Net income attributable to Zoetis $ 345   $ 81   * $ 1,428   $ 864   65
 
Earnings per share—basic $ 0.72   $ 0.17   * $ 2.96   $ 1.76   68
 
Earnings per share—diluted $ 0.71   $ 0.16   * $ 2.93   $ 1.75   67
 
Weighted-average shares used to calculate earnings per share (in
thousands)
Basic 480,603   487,323   483,063   489,918  
Diluted 484,479   491,022   486,898   493,161  
 
* Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.

(a) The consolidated statements of income present the
three and twelve months ended December 31, 2018 and 2017.
Subsidiaries operating outside the United States
are included
for the three and twelve months ended November 30, 2018 and 2017.

(b) Exclusive of amortization of intangible assets,
except as discussed in footnote (c) below.

(c) Amortization expense related to finite-lived
acquired intangible assets that contribute to our ability to sell,
manufacture, research, market and distribute products,
compounds
and intellectual property is included in Amortization of
intangible assets
as these intangible assets benefit multiple
business functions. Amortization
expense related to
finite-lived acquired intangible assets that are associated with a
single function is included in Cost of sales, Selling, general
and administrative
expenses
or Research and
development expenses
, as appropriate.

       

ZOETIS INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars, except per share data)

   
Quarter Ended December 31, 2018

GAAP
Reported(a)

   

Purchase
Accounting
Adjustments(1)

   

Acquisition-
Related
Costs(2)

   

Certain
Significant
Items(3)

   

Non-GAAP
Adjusted(b)

Cost of sales(c) $ 544 $ (14 ) $ $ (4 ) $ 526
Gross profit 1,020 14 4 1,038
Selling, general and administrative expenses(c) 420 (18 ) (1 ) 401
Research and development expenses(c) 125 (1 ) 124
Amortization of intangible assets(d) 39 (34 ) 5
Restructuring charges and certain acquisition-related costs 14 (22 ) 8
Other (income)/deductions–net (55 ) 42 (13 )
Income before provision for taxes on income 418 67 22 (45 ) 462
Provision for taxes on income 73 16 4 (13 ) 80
Net income attributable to Zoetis 345 51 18 (32 ) 382
Earnings per common share attributable to Zoetis–diluted 0.71 0.11 0.04 (0.07 ) 0.79
 
Quarter Ended December 31, 2017

GAAP
Reported(a)

Purchase
Accounting
Adjustments(1)

Acquisition-
Related
Costs(2)

Certain
Significant
Items(3)

Non-GAAP
Adjusted(b)

Cost of sales(c) $ 457 $ (2 ) $ $ (1 ) $ 454
Gross profit 1,003 2 1 1,006
Selling, general and administrative expenses(c) 361 (1 ) (1 ) 359
Research and development expenses(c) 110 110
Amortization of intangible assets(d) 23 (19 ) 4
Restructuring charges and certain acquisition-related costs 12 (2 ) (10 )
Other (income)/deductions–net 17 (3 ) 14
Income before provision for taxes on income 430 22 2 15 469
Provision for taxes on income 350 21 (242 ) 129
Net income attributable to Zoetis 81 1 2 257 341
Earnings per common share attributable to Zoetis–diluted 0.16 0.53 0.69

Certain amounts may reflect rounding adjustments.

       

ZOETIS INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars, except per share data)

   
Twelve Months Ended December 31, 2018

GAAP
Reported(a)

   

Purchase
Accounting
Adjustments(1)

   

Acquisition-
Related
Costs(2)

   

Certain
Significant
Items(3)

   

Non-GAAP
Adjusted(b)

Cost of sales(c) $ 1,911 $ (27 ) $ $ (8 ) $ 1,876
Gross profit 3,914 27 8 3,949
Selling, general and administrative expenses(c) 1,484 (32 ) (2 ) 1,450
Research and development expenses(c) 432 (2 ) 430
Amortization of intangible assets(d) 117 (101 ) 16
Restructuring charges and certain acquisition-related costs 68 (63 ) (5 )
Other (income)/deductions–net (83 ) 58 (25 )
Income before provision for taxes on income 1,690 162 63 (43 ) 1,872
Provision for taxes on income 266 43 13 29 351
Net income attributable to Zoetis 1,428 119 50 (72 ) 1,525
Earnings per common share attributable to Zoetis–diluted 2.93 0.24 0.10 (0.14 ) 3.13
 
Twelve Months Ended December 31, 2017

GAAP
Reported(a)

Purchase
Accounting
Adjustments(1)

Acquisition-
Related
Costs(2)

Certain
Significant
Items(3)

Non-GAAP
Adjusted(b)

Cost of sales(c) $ 1,775 $ (7 ) $ $ (7 ) $ 1,761
Gross profit 3,532 7 7 3,546
Selling, general and administrative expenses(c) 1,334 (5 ) (4 ) 1,325
Research and development expenses(c) 382 (2 ) 380
Amortization of intangible assets(d) 91 (74 ) 17
Restructuring charges and certain acquisition-related costs 19 (10 ) (9 )
Other (income)/deductions–net 6 (5 ) 1
Income before provision for taxes on income 1,525 88 10 25 1,648
Provision for taxes on income 663 37 3 (238 ) 465
Net income attributable to Zoetis 864 51 7 263 1,185
Earnings per common share attributable to Zoetis–diluted 1.75 0.10 0.01 0.54 2.40
Certain amounts may reflect rounding adjustments.

(a) The consolidated statements of income present the
three and twelve months ended December 31, 2018 and 2017.
Subsidiaries operating outside the United States are included for
the
three and twelve months ended November 30, 2018 and 2017.

(b) Non-GAAP adjusted net income and its components and
non-GAAP adjusted diluted EPS are not, and should not be viewed
as, substitutes for U.S. GAAP net income and its
components
and diluted EPS. Despite the importance of these measures to
management in goal setting and performance measurement, non-GAAP
adjusted net income and its
components and non-GAAP adjusted
diluted EPS are non-GAAP financial measures that have no
standardized meaning prescribed by U.S. GAAP and, therefore, have
limits in their
usefulness to investors. Because of the
non-standardized definitions, non-GAAP adjusted net income and its
components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net
income
and its components and diluted EPS) may not be comparable to the
calculation of similar measures of other companies. Non-GAAP
adjusted net income and its components and
non-GAAP adjusted
diluted EPS are presented solely to permit investors to more fully
understand how management assesses performance.

(c) Exclusive of amortization of intangible assets,
except as discussed in footnote (d) below.

(d) Amortization expense related to finite-lived
acquired intangible assets that contribute to our ability to sell,
manufacture, research, market and distribute products, compounds
and
intellectual property is included in Amortization of
intangible assets
as these intangible assets benefit multiple
business functions. Amortization expense related to acquired
intangible
assets that are associated with a single function
is included in Cost of sales, Selling, general and
administrative expenses
or Research and development expenses,
as appropriate.

See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted
Information for notes (1), (2) and (3).
             

ZOETIS INC.

NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED
INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars)

 

       

(1) Income taxes in Purchase accounting adjustments for
2017 includes a provisional tax benefit of $17 million related to
the
remeasurement of the company’s deferred taxes due to the
reduction in the U.S. federal corporate tax rate as provided by
the U.S. Tax Cuts and Jobs Act enacted on
December 22, 2017.

 

(2) Acquisition-related costs include the following:

 
Fourth Quarter Full Year
2018   2017 2018   2017
Transaction costs(a) $ $ $ 21 $
Integration costs(b) 11 2 21 6
Restructuring charges(c) 11     21   4
Total acquisition-related costs—pre-tax 22 2 63 10
Income taxes(d) 4     13   3
Total acquisition-related costs—net of tax $ 18   $ 2   $ 50   $ 7
Certain amounts may reflect rounding adjustments.

(a) Represents external costs directly related to
acquiring businesses and primarily includes expenditures for
banking, legal, accounting and other similar services.
Included
in Restructuring charges and certain acquisition-related costs.

(b) Represents external, incremental costs directly
related to integrating acquired businesses and primarily includes
expenditures for consulting and the integration of
systems
and processes. Included in Restructuring charges and certain
acquisition-related costs
.

(c) Represents employee termination costs related to
the 2018 acquisition of Abaxis and the 2017 acquisition of an
Irish biologic therapeutics company.
Included in Restructuring
charges and certain acquisition-related costs
.

(d) Included in Provision for taxes on income.
Represents the tax effect of the associated pre-tax
acquisition-related amounts, calculated by determining the
jurisdictional
location of the pre-tax amounts and applying that jurisdiction’s
applicable tax rate. For the twelve months ended December 31,
2018, also includes a
tax charge related to the
non-deductibility of certain costs associated with the 2018
acquisition of Abaxis.

(3) Certain significant items include the following:

       
Fourth Quarter Full Year
2018   2017 2018   2017
Operational efficiency initiative(a) $ (1 ) $ 1 $ (1 ) $ 5
Supply network strategy(a) 2 8 10 15
Other restructuring charges and cost-reduction/productivity
initiatives(b)
(4 ) 4 7 4
Net gain on sale of assets(c) (42 ) (42 )
Stand-up costs(d) 3 3
Other(e)   (1 ) (17 ) (2 )
Total certain significant items—pre-tax (45 ) 15 (43 ) 25
Income taxes(f) (13 ) (242 ) 29   (238 )
Total certain significant items—net of tax $ (32 ) $ 257   $ (72 ) $ 263  
Certain amounts may reflect rounding adjustments.

(a) Represents consulting fees and product transfer
costs, adjustments to inventory reserves and accelerated
depreciation included in Cost of sales, consulting fees
included
in Selling, general and administrative expenses, employee
termination costs and exit costs included in Restructuring
charges and certain acquisition-
related costs
, and net
(gains)/losses on sales of certain manufacturing sites and
products included in Other (income)/deductions—net, related
to cost-reduction and
productivity initiatives.

(b) Represents employee termination costs/(reversals)
in Europe as a result of initiatives to better align our
organizational structure, included in Restructuring charges
and
certain acquisition-related costs
.

(c) Represents a net gain related to the divestiture of
certain agribusiness products within our International segment,
included in Other (income)/deductions—net.

(d) Represents certain nonrecurring costs related to
becoming an independent public company, such as the creation of
standalone systems and infrastructure, site
separation, new
branding (including changes to the manufacturing process for
required new packaging), and certain legal registration and patent
assignment costs,
included in Cost of sales.

(e) For 2018, primarily represents a net gain related
to the relocation of a manufacturing site in China, included in Other
(income)/deductions—net
.

For 2017, primarily represents costs associated with changes to
our operating model in Cost of sales and Selling, general and
administrative expenses
, and income
related to an
insurance recovery from commercial settlements in Mexico recorded
in 2014 and 2016, included in Other (income)/deductions—net.

(f) Included in Provision for taxes on income.
Represents the tax effect of the associated pre-tax certain
significant items amounts, calculated by determining the
jurisdictional
location of the pre-tax amounts and applying that jurisdiction’s
applicable tax rate.

For 2018, also includes (i) a net tax benefit of $45 million
related to a measurement period adjustment to the one-time
mandatory deemed repatriation tax on the
company’s
undistributed non-U.S. earnings, pursuant to the Tax Cuts and Jobs
Act enacted on December 22, 2017, and (ii) a tax charge of
approximately $17
million related to the disposal of certain
assets.

For 2017, also includes (i) a provisional net tax charge of $229
million related to the impact of the Tax Cuts and Jobs Act enacted
on December 22, 2017,
including a one-time mandatory deemed
repatriation tax on the company’s undistributed non-U.S. earnings,
partially offset by a tax benefit related to the
remeasurement
of the company’s deferred tax assets and liabilities, as of the
date of enactment, due to the reduction in the U.S. federal
corporate tax rate, (ii) a net
tax charge of approximately $3
million as a result of the implementation of certain operational
changes, and (iii) a tax charge of approximately $2 million related
to
the disposal of certain assets.

               

ZOETIS INC.

ADJUSTED SELECTED COSTS AND EXPENSES(a)

(UNAUDITED)

(millions of dollars)

         
Fourth Quarter % Change
2018     2017 Total      

Foreign
Exchange

    Operational(b)
Adjusted cost of sales $ 526 $ 454 16 % 1% 15%
As a percent of revenue 33.6 % 31.1 % NA NA NA
Adjusted SG&A expenses $ 401 $ 359 12 % (3)% 15%
Adjusted R&D expenses 124 110 13 % (1)% 14%
Adjusted net income attributable to Zoetis 382 341 12 % (9)% 21%
 
 
 
Full Year % Change
2018 2017 Total

Foreign
Exchange

Operational(b)
Adjusted cost of sales $ 1,876 $ 1,761 7 % 2% 5%
As a percent of revenue 32.2 % 33.2 % NA NA NA
Adjusted SG&A expenses $ 1,450 $ 1,325 9 % —% 9%
Adjusted R&D expenses 430 380 13 % —% 13%
Adjusted net income attributable to Zoetis 1,525 1,185 29 % (2)% 31%
Certain amounts and percentages may reflect rounding adjustments.

(a) Adjusted cost of sales, adjusted selling, general,
and administrative (SG&A) expenses, adjusted research and
development (R&D) expenses, and adjusted net
income
attributable to Zoetis are defined as the corresponding reported
U.S. generally accepted accounting principles (GAAP) income
statement line items
excluding purchase accounting
adjustments, acquisition-related costs, and certain significant
items. Reconciliations of certain reported to adjusted information
for
the three and twelve months ended December 31, 2018 and
2017 are provided in the materials accompanying this report. These
adjusted income statement line
item measures are not, and
should not be viewed as, substitutes for the corresponding U.S.
GAAP line items. For the corresponding GAAP line items, see
Consolidated
Statements of Income and Reconciliation of GAAP Reported to
Non-GAAP Adjusted Information.

(b) Operational growth (a non-GAAP financial measure)
is defined as growth excluding the impact of foreign exchange.

       

ZOETIS INC.

2019 GUIDANCE

   
Selected Line Items

(millions of dollars, except per share amounts)

    Full Year 2019
Revenue $6,175 to $6,300
Operational growth(a) 7.5% to 9.5%
Organic operational growth(b)     4.5% to 6.5%
Adjusted cost of sales as a percentage of revenue(c)     31% to 32%
Adjusted SG&A expenses(c)     $1,470 to $1,520
Adjusted R&D expenses(c)     $445 to $465
Adjusted interest expense and other (income)/deductions(c)     Approximately $220
Effective tax rate on adjusted income(c)     20% to 21%
Adjusted diluted EPS(c)     $3.42 to $3.52
Adjusted net income(c) $1,650 to $1,700
Operational growth(a)(d)     8% to 11%
Certain significant items and acquisition-related costs(e)     $90 to $120
 
The guidance reflects foreign exchange rates as of late January 2019.
Reconciliations of 2019 reported guidance to 2019 adjusted guidance
follows:
 
                         
(millions of dollars, except per share amounts)     Reported    

Certain significant
items and
acquisition-related
costs(e)

   

Purchase
accounting

    Adjusted(b)
               
Cost of sales as a percentage of revenue     32.5% – 33.5%     ~ (1.0%)     ~ (0.5%)     31% – 32%
SG&A expenses     $1,545 to $1,595           ($75)     $1,470 to $1,520
R&D expenses     $447 to $467           ($2)     $445 to $465
Interest expense and other (income)/deductions     ~ $220                 ~ $220
Effective tax rate     20% to 21%                 20% to 21%
Diluted EPS     $2.83 to $2.99     $0.15 to $0.22     $0.37     $3.42 to $3.52
Net income attributable to Zoetis     $1,365 to $1,445     $75 to $105     ~ $180     $1,650 to $1,700

(a) Operational growth (a non-GAAP financial measure)
excludes the impact of foreign exchange.

(b) Organic operational growth (a non-GAAP financial
measure) excludes the impact of the acquisition of Abaxis as well
as foreign exchange.

(c) Adjusted net income and its components and adjusted
diluted EPS are defined as reported U.S. generally accepted
accounting principles (GAAP) net income and
its components
and reported diluted EPS excluding purchase accounting
adjustments, acquisition-related costs and certain significant
items. Adjusted cost of sales,
adjusted selling, general and
administrative (SG&A) expenses, adjusted research and development
(R&D) expenses, and adjusted interest expense and other
(income)/deductions
are income statement line items prepared on the same basis, and,
therefore, components of the overall adjusted income measure.
Despite the
importance of these measures to management in
goal setting and performance measurement, adjusted net income and
its components and adjusted diluted EPS are
non-GAAP
financial measures that have no standardized meaning prescribed by
U.S. GAAP and, therefore, have limits in their usefulness to
investors. Because of
the non-standardized definitions,
adjusted net income and its components and adjusted diluted EPS
(unlike U.S. GAAP net income and its components and diluted
EPS)
may not be comparable to the calculation of similar measures of
other companies. Adjusted net income and its components and
adjusted diluted EPS are
presented solely to permit investors
to more fully understand how management assesses performance.
Adjusted net income and its components and adjusted
diluted
EPS are not, and should not be viewed as, substitutes for U.S.
GAAP net income and its components and diluted EPS.

(d) We do not provide a reconciliation of
forward-looking non-GAAP adjusted net income operational growth to
the most directly comparable GAAP reported
financial measure
because we are unable to calculate with reasonable certainty the
foreign exchange impact of unusual gains and losses,
acquisition-related
expenses, potential future asset
impairments and other certain significant items, without
unreasonable effort. The foreign exchange impacts of these items
are
uncertain, depend on various factors, and could have a
material impact on GAAP reported results for the guidance period.

(e) Primarily includes certain nonrecurring costs
related to the acquisition of Abaxis and other charges.

             

ZOETIS INC.

CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES

(UNAUDITED)

(millions of dollars)

       
Fourth Quarter % Change
2018     2017 Total    

Foreign
Exchange

    Operational(b)
Revenue:
Livestock $ 872 $ 891 (2 )% (4)% 2%
Companion Animal 664 561 18 % (3)% 21%
Contract Manufacturing & Human Health Diagnostics 28   8   * * *
Total Revenue $ 1,564   $ 1,460   7 % (4)% 11%
 
U.S.
Livestock $ 384 $ 374 3 % —% 3%
Companion Animal 425   338   26 % —% 26%
Total U.S. Revenue $ 809   $ 712   14 % —% 14%
 
International
Livestock $ 488 $ 517 (6 )% (8)% 2%
Companion Animal 239   223   7 % (7)% 14%
Total International Revenue $ 727   $ 740   (2 )% (7)% 5%
 
Livestock:
Cattle $ 525 $ 543 (3 )%

(4)%

1%
Swine 163 166 (2 )% (5)% 3%
Poultry 127 122 4 % (4)% 8%
Fish 40 39 3 % (5)% 8%
Other 17   21   (19 )% (3)% (16)%
Total Livestock Revenue $ 872   $ 891   (2 )% (4)% 2%
 
Companion Animal:
Dogs and Cats $ 613 $ 514 19 % (3)% 22%
Horses 51   47   9 % (3)% 12%
Total Companion Animal Revenue $ 664   $ 561   18 % (3)% 21%
* Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.

(a) For a description of each segment, see Zoetis’ most
recent Annual Report on Form 10-K.

(b) Operational revenue growth (a non-GAAP financial
measure) is defined as revenue growth excluding the impact of
foreign exchange.

           

ZOETIS INC.

CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES

(UNAUDITED)

(millions of dollars)

     
Full Year % Change
2018   2017 Total    

Foreign
Exchange

    Operational(b)
Revenue:
Livestock $ 3,154 $ 3,037 4 % —% 4%
Companion Animal 2,613 2,226 17 % —% 17%
Contract Manufacturing & Human Health Diagnostics 58   44   32 % 1% 31%
Total Revenue $ 5,825   $ 5,307   10 % —% 10%
 
U.S.
Livestock $ 1,269 $ 1,244 2 % —% 2%
Companion Animal 1,608   1,376   17 % —% 17%
Total U.S. Revenue $ 2,877   $ 2,620   10 % —% 10%
 
International
Livestock $ 1,885 $ 1,793 5 % (1)% 6%
Companion Animal 1,005   850   18 % 1% 17%
Total International Revenue $ 2,890   $ 2,643   9 % —% 9%
 
Livestock:
Cattle $ 1,754 $ 1,735 1 % (1)% 2%
Swine 663 621 7 % 1% 6%
Poultry 522 479 9 % —% 9%
Fish 132 118 12 % —% 12%
Other 83   84   (1 )% 1% (2)%
Total Livestock Revenue $ 3,154   $ 3,037   4 % —% 4%
 
Companion Animal:
Dogs and Cats 2,445 2,075 18 % 1% 17%
Horses 168   151   11 % 1% 10%
Total Companion Animal Revenue $ 2,613   $ 2,226   17 % —% 17%
* Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.

(a) For a description of each segment, see Zoetis’ most
recent Annual Report on Form 10-K.

(b) Operational revenue growth (a non-GAAP financial
measure) is defined as revenue growth excluding the impact of
foreign exchange.

       

ZOETIS INC.

CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS

(UNAUDITED)

(millions of dollars)

 
Fourth Quarter % Change
2018   2017 Total    

Foreign
Exchange

  Operational(a)
Total International       $ 727.2     $ 739.5     (2 )% (7)%   5%
Australia 36.8 41.5 (11 )% (7)% (4)%
Brazil 84.6 95.2 (11 )% (19)% 8%
Canada 64.4 61.3 5 % (5)% 10%
China 41.3 37.2 11 % (5)% 16%
France 38.3 36.3 6 % (2)% 8%
Germany 34.9 41.0 (15 )% (2)% (13)%
Italy 24.5 23.6 4 % (2)% 6%
Japan 34.9 36.6 (5 )% (1)% (4)%
Mexico 26.2 25.5 3 % (6)% 9%
Spain 26.8 25.5 5 % (3)% 8%
United Kingdom 46.1 44.2 4 % (2)% 6%
Other Developed 95.5 99.4 (4 )% (3)% (1)%
Other Emerging 172.9 172.2 % (11)% 11%
 
Full Year % Change
2018 2017 Total

Foreign
Exchange

Operational(a)
Total International       $ 2,889.8  

 

  $ 2,642.9     9 % —%   9%
Australia 188.6 175.6 7 % (2)% 9%
Brazil 294.7 299.8 (2 )% (13)% 11%
Canada 202.8 184.4 10 % 1% 9%
China 211.4 174.4 21 % 4% 17%
France 129.8 121.0 7 % 5% 2%
Germany 146.8 137.2 7 % 6% 1%
Italy 104.0 88.8 17 % 6% 11%
Japan 149.0 137.8 8 % 2% 6%
Mexico 100.0 85.8 17 % —% 17%
Spain 109.9 92.7 19 % 7% 12%
United Kingdom 181.2 149.2 21 % 5% 16%
Other Developed 361.4 339.4 6 % 2% 4%
Other Emerging 710.2 656.8 8 % (3)% 11%
Certain amounts and percentages may reflect rounding adjustments.

(a) Operational growth (a non-GAAP financial measure)
is defined as growth excluding the impact of foreign exchange.

             

ZOETIS INC.

SEGMENT(a) EARNINGS

(UNAUDITED)

(millions of dollars)

       
Fourth Quarter % Change
2018     2017 Total    

Foreign
Exchange

    Operational(b)

U.S.:

Revenue $ 809 $ 712 14 % —% 14%
Cost of sales 175   153   14 % —% 14%
Gross profit 634 559 13 % —% 13%
Gross margin 78.4 % 78.5 %
Operating expenses 128 109 17 % —% 17%
Other (income)/deductions   (3 ) * * *
U.S. Earnings $ 506 $ 453 12 % —% 12%
 

International:

Revenue $ 727 $ 740 (2 )% (7)% 5%
Cost of sales 240   244   (2 )% (5)% 3%
Gross profit 487 496 (2 )% (9)% 7%
Gross margin 67.0 % 67.0 %
Operating expenses 148 143 3 % (7)% 10%
Other (income)/deductions 1     * * *
International Earnings $ 338 $ 353 (4 )% (9)% 5%
 
Total Reportable Segments $ 844 $ 806 5 % (4)% 9%
 
Other business activities(c) (90 ) (89 ) 1 %
Reconciling Items:
Corporate(d) (196 ) (188 ) 4 %
Purchase accounting adjustments(e) (67 ) (22 ) *
Acquisition-related costs(f) (22 ) (2 ) *
Certain significant items(g) 45 (15 ) *
Other unallocated(h) (96 ) (60 ) 60 %
Total Earnings(i) $ 418   $ 430   (3 )%
* Calculation not meaningful
Certain amounts and percentages may reflect rounding adjustments.

(a) For a description of each segment, see Zoetis’ most
recent Annual Report on Form 10-K.

(b) Operational growth (a non-GAAP financial measure)
is defined as growth excluding the impact of foreign exchange.

(c) Other business activities reflect the research and
development costs managed by our Research and Development
organization as well as our contract manufacturing business
and
human health diagnostics business.

(d) Corporate includes, among other things,
administration expenses, interest expense, certain compensation
and other costs not charged to our operating segments.

(e) Purchase accounting adjustments include certain
charges related to the amortization of fair value adjustments to
inventory, intangible assets and property, plant and
equipment
not charged to our operating segments.

(f) Acquisition-related costs include costs associated
with acquiring and integrating newly acquired businesses, such as
transaction costs and integration costs.

(g) Certain significant items includes substantive,
unusual items that, either as a result of their nature or size,
would not be expected to occur as part of our normal business on a
regular
basis. Such items primarily include restructuring charges and
implementation costs associated with our
cost-reduction/productivity initiatives that are not associated
with
an acquisition, costs associated with the operational efficiency
initiative and supply network strategy, certain legal and
commercial settlements, and the impact of
divestiture-related
gains and losses.

(h) Includes overhead expenses associated with our
manufacturing and supply operations not directly attributable to
an operating segment, as well as procurement costs.

(i) Defined as income before provision for taxes on
income.

             

ZOETIS INC.

SEGMENT(a) EARNINGS

(UNAUDITED)

(millions of dollars)

       
Full Year % Change
2018     2017 Total    

Foreign
Exchange

  Operational(b)
U.S.:
Revenue $ 2,877 $ 2,620 10 % —% 10%
Cost of sales 606   565   7 % —% 7%
Gross profit 2,271 2,055 11 % —% 11%
Gross margin 78.9 % 78.4 %
Operating expenses 456 421 8 % —% 8%
Other (income)/deductions   (3 ) * * *
U.S. Earnings $ 1,815 $ 1,637 11 % —% 11%
 

International:

Revenue $ 2,890 $ 2,643 9 % —% 9%
Cost of sales 929   889   4 % —% 4%
Gross profit 1,961 1,754 12 % —% 12%
Gross margin 67.9 % 66.4 %
Operating expenses 559 515 9 % —% 9%
Other (income)/deductions 3   (1 ) * * *
International Earnings $ 1,399 $ 1,240 13 % —% 13%
 
Total Reportable Segments $ 3,214 $ 2,877 12 % —% 12%
 
Other business activities(c) (337 ) (313 ) 8 %
Reconciling Items:
Corporate(d) (666 ) (625 ) 7 %
Purchase accounting adjustments(e) (162 ) (88 ) 84 %
Acquisition-related costs(f) (63 ) (10 ) *
Certain significant items(g) 43 (25 ) *
Other unallocated(h) (339 ) (291 ) 16 %
Total Earnings(i) $ 1,690   $ 1,525   11 %
* Calculation not meaningful
Certain amounts and percentages may reflect rounding adjustments.

(a) For a description of each segment, see Zoetis’ most
recent Annual Report on Form 10-K.

(b) Operational growth (a non-GAAP financial measure)
is defined as growth excluding the impact of foreign exchange.

(c) Other business activities reflect the research and
development costs managed by our Research and Development
organization as well as our contract manufacturing business and
human health diagnostics business.

(d) Corporate includes, among other things,
administration expenses, interest expense, certain compensation
and other costs not charged to our operating segments.

(e) Purchase accounting adjustments include certain
charges related to the amortization of fair value adjustments to
inventory, intangible assets and property, plant and equipment not
charged to our operating segments.

(f) Acquisition-related costs include costs associated
with acquiring and integrating newly acquired businesses, such as
transaction costs and integration costs.

(g) Certain significant items includes substantive,
unusual items that, either as a result of their nature or size,
would not be expected to occur as part of our normal business on a
regular basis. Such items primarily include restructuring charges
and implementation costs associated with our
cost-reduction/productivity initiatives that are not associated
with an acquisition, costs associated with the operational
efficiency initiative and supply network strategy, certain legal
and commercial settlements, and the impact of divestiture-related
gains and losses.

(h) Includes overhead expenses associated with our
manufacturing and supply operations not directly attributable to
an operating segment, as well as procurement costs.

(i) Defined as income before provision for taxes on
income.

Contacts

Media Contacts:
Elinore White
1-973-443-2835
(o)
elinore.y.white@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Investor Contacts:
Steve Frank
1-973-822-7141
(o)
steve.frank@zoetis.com

Marissa Patel
1-973-443-2996 (o)
marissa.patel@zoetis.com

Source: Zoetis Inc.


Voir aussi

Study Demonstrates Cook Biotech’s OASIS® Wound Matrix Has Higher Rates of Healing in Pressure Ulcers Than Standard of Care

Wednesday, February 20th 2019 at 6:30pm UTC BLOOMINGTON, Ind.–(BUSINESS WIRE)– A recently published multi-center, randomized, …